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The neutrophil-to-lymphocyte and
monocyte-to-lymphocyte ratios are
independently associated with neurological
disability and brain atrophy in multiple
sclerosis
Christopher C. Hemond1,2,3* , Bonnie I. Glanz2,3, Rohit Bakshi2,3,4, Tanuja Chitnis2,3 and Brian C. Healy2,3
Abstract
Background: Serum hematological indices such as the neutrophil-lymphocyte ratio (NLR) or monocyte-lymphocyte
ratio (MLR) have been used as biomarkers of pathogenic inflammation and prognostication in multiple areas of
medicine; recent evidence shows correlation with psychological parameters as well.
Objectives/Aims: To characterize clinical, neuroimaging, and psycho-neuro-immunological associations with NLR
and MLR in persons with multiple sclerosis (MS).
Methods: We identified a large cohort of clinically well-defined patients from our longitudinal database that
included MS-related outcomes, disease-modifying therapy, patient-reported outcome (PRO) measures, and
quantified cerebral MRI at 1.5 T. We queried hospital records for complete blood counts within 2 months of each
clinic visit and excluded those obtained during clinical relapses. Four hundred eighty-three patients, with a mean of
3 longitudinal observations each, were identified who met these criteria. Initial analyses assessed the association
between NLR and MLR as the outcomes, and psychological and demographic predictors in univariable and
multivariable models controlling for age, gender and treatment. The second set of analyses assessed the association
between clinical and MRI outcomes including whole brain atrophy and T2-hyperintense lesion volume, with NLR
and MLR as predictors in univariable and multivariable models. All analyses used a mixed effects linear or logistic
regression model with repeated measures.
Results: Unadjusted analyses demonstrated significant associations between higher (log-transformed) NLR (but not
MLR) and PRO measures including increasing depression (p = 0.01), fatigue (p < 0.01), and decreased physical quality
of life (p < 0.01). Higher NLR and MLR strongly predicted increased MS-related disability as assessed by the
Expanded Disability Status Scale, independent of all demographic, clinical, treatment-related, and psychosocial
variables (p < 0.001). Lastly, higher NLR and MLR significantly discriminated progressive from relapsing status (p≤ 0.01
for both), and higher MLR correlated with increased whole-brain atrophy (p < 0.05) but not T2 hyperintense lesion
volume (p > 0.05) even after controlling for all clinical and demographic covariates. Sensitivity analyses using a subset
of untreated patients (N = 146) corroborated these results.
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Conclusions: Elevated NLR and MLR may represent hematopoetic bias toward increased production and pro-
inflammatory priming of the myeloid innate immune system (numerator) in conjunction with dysregulated adaptive
immune processes (denominator), and consequently reflect a complementary and independent marker for severity of
MS-related neurological disability and MRI outcomes.




Multiple sclerosis (MS) is a progressive neurodegenerative
condition of presumed autoimmune etiology typically
characterized by recurrent episodes of inflammatory de-
myelination and accelerated tissue destruction of the cen-
tral nervous system. The etiology of the disease is thought
to principally involve the peripheral activation of Th1 lym-
phocytes which traffic to the central nervous system and
react with myelin autoantigens. Following activation, these
T-cells recruit a diverse set of myeloid cells including
monocytes/macrophages to promote and execute an in-
flammatory reaction, frequently causing axonal transec-
tion and irreversible focal central nervous system (CNS)
injury [1]. In addition to monocytes, neutrophils have also
recently been implicated to play a role in augmentation of
the inflammatory response in MS [2].
The neutrophil-lymphocyte ratio (NLR) and
monocyte-lymphocyte ratio (MLR) are inexpensive and
readily available components of the standard complete
blood count (CBC); they are increasingly recognized as
clinically-relevant biomarkers of pathological inflamma-
tion across multiple areas of medicine including oncol-
ogy [3, 4], cardiovascular disease [5], and autoimmune
conditions [6]. In neurology, NLR improves outcome
prediction in stroke [7, 8], and is elevated compared to
healthy controls in degenerative conditions like Alzhei-
mer’s [9, 10] and Parkinson’s [11] disease.
The NLR and MLR have also been linked to psycho-
logical parameters. The NLR has a well-established
short-term response to both endogenous and exogenous
corticosteroids [12] and links to perceived stress in
humans [13]. A recent meta-analysis concluded that there
is an elevated NLR in several mood disorders including
depression [14]. In a population of patients with stable
coronary artery disease, Serfozo and colleagues showed a
strong independent correlation (after controlling for
age, body mass index and sex) between the MLR and
depression symptom severity score, as well as other
inflammatory markers (IL-6, C-Reactive Protein), and
neuroendocrine-sympathetic activity as measured by
chromogranin A [15]. It has been proposed that psy-
chosocial stress and related chronic psychiatric dis-
eases (depression, anxiety) may bias the hemopoetic
differentiation process toward both (1) increased produc-
tion of monocytes and granulocytes and (2) enhance mye-
loid pro-inflammatory ‘priming’ and trafficking, both via
bidirectional interactions between CNS sympathic/neuro-
endocrine systems and lymphoid tissue [16–18]. Irrespect-
ive of psychosocial factors however, both neutrophils and
monocytes have been observed to be ‘primed’ for
pro-inflammatory activity in persons with multiple scler-
osis, thought to be related to the chronic systemic inflam-
matory environment of this disease [2, 19].
There is limited prior literature regarding the NLR in
MS; Demirci and colleagues were the first to explore this
area and found that an elevated NLR could discriminate
MS from healthy controls, was related to neurological
disability scores, and was further increased in flares
compared to remission [20]. Several subsequent studies
have confirmed similar findings [13, 20, 21], although
one study could not replicate associations with disability
scores [22]. None of these studies carefully examined the
role of disease-modifying therapies however; nor did
they look at MRI-related disease outcomes such as cere-
bral atrophy or quantified T2-hyperintense lesion vol-
ume. The role of MLR has not been studied in MS to
our knowledge. This work has been previously published
in abstract format [23].
Objectives/aims
Here we hypothesize that the NLR and MLR are
psycho-neuro-immunological markers; modulated in part
by factors such as stress, depression, and social isolation/
support. Furthermore, we hypothesize that the NLR and
MLR play a role in MS-related disability by contributing
to (or reflecting) a pro-inflammatory state. To this end,
our first aim was to establish whether a relationship exists
between the NLR/MLR and demographic variables in-
cluding age and sex, as well as MS-related clinical pheno-
types, disease duration, and disease-modifying therapies.
Second, we sought to better understand associations be-
tween the NLR/MLR and patient-reported psychological
outcomes including mental health, social support, depres-
sion, and quality of life. Third, we aimed to explore associ-
ations with objective markers of neuroinflammation and
degeneration as reflected by neurological disability and
MRI neuroimaging parameters relevant in MS, including
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This is a retrospective analysis of prospectively-collected
data in a cohort of multiple sclerosis subjects who partici-
pated in the Comprehensive Longitudinal Investigation of
Multiple Sclerosis at the Brigham and Women’s Hospital,
Partners MS Center (CLIMB). CLIMB is an ongoing, pro-
spective observational cohort study, started in 2000 [24].
General inclusion criteria to participate include: age ≥ 18
years and a diagnosis of relapsing-spectrum or progressive
MS syndrome based on revised McDonald Criteria [25].
MS participants are examined at a minimum of every 12
months by a neurologist with subspecialty MS training;
demographic and clinical data are regularly collected as
part of this study. Additionally, a subset of patients con-
sented to complete patient-reported outcome measures
(PRO) as detailed below. Additional inclusion criteria
for this specific study were: age < 65, and a CBC with
differential within 60 days of their patient-reported
outcome assessment. Exclusion criteria included:
CBC-d obtained on the same day or the following 1
month after reported clinical flare, or multiple CBCs
within 4 days of each other which were thought to
have a high probability of being obtained during
times of infection or inpatient hospitalization. In total,
483 patients were included in the analysis, with a
mean of 3.0 observations each (range: 1–10) for a
total of 1433 observations. Subject demographics,
clinical characteristics, patient self-reported outcome
measures, and neuroimaging data are summarized in
Table 1.
Consent to participate
This study was reviewed and approved by the Partners
Human Research Committee ethics board at the Brigham
and Women’s Hospital (IRB Protocol # 1999-P-010435).
All research subjects provided informed written consent.
Patient-reported measures
Four patient-reported psychological questionnaires are
administered to a subset of participants in the CLIMB
study as follows. The 20-item Center for Epidemiology
Depression scale (CES-D) [26] is a validated scale that
focuses on the cognitive and affective rather than the
somatic components of depression. Scores range from
20 to 80 and a cutoff of ≥36 is considered to be in the
depressed range. The 21-item Modified Fatigue Inven-
tory Scale (MFIS) [27] assesses physical, cognitive, and
psychosocial fatigue with a score range from 0 to 84; a
cutoff of ≥38 represents clinically meaningful fatigue.
The SF-36 [28] is an inventory of mental, physical, and
social measures of life satisfaction and fitness that as-
sesses eight health concepts and is summarized in two
composite scores of physical and mental quality of life.
The 18-item Medical Outcomes Modified Study Social
Support Survey (MSSS) [29] is an assessment of patient’s
perceived social support with four subscales and raw
scores ranging from 18 to 90. PROs were administered
annually at study inception (2000) until 2011 when they
began being collected biennially. The exception is the
MFIS, which was added on 6/23/2006.
Complete blood counts
Automated complete blood counts with differential were
obtained via an electronic query of hospital records. Per-
sonal communication with hematology, as well as refer-
ence test numbers, confirmed the use of two automated
hematological analysis machines during the data collec-
tion period: Siemens ADVIA 2120 was used prior to 10/
29/2011 and a SYSMEX XE 5000 was used after 10/29/
2011. The vast majority of the data were from the
ADVIA 2120, so measurements from the SYSMEX XE
were excluded from the study to reduce variability (see
Discussion).
Neuroimaging
Brain MRI scans were acquired at 1.5 T from several
Signa GE scanners with similar dual-echo spin-echo acqui-
sition parameters: TR = 2800–3000msec, TE1/TE2 = 30/80
msec, slice thickness = 3mm (gapless), pixel size = 0.93 ×
0.93mm. Brain parenchymal fraction (BPF) and cerebral
T2-hyperintense lesion volumes (T2LV) were obtained
from automated template-driven segmentation [30] with
additional expert manual correction as required. Brain
parenchymal fraction was defined as the summation
of cerebral gray and white matter divided by volume
of the intracranial cavity to yield a self-normalized
fraction. T2LV was quantified a summated single volume
measurement.
Statistical analysis
Statistical analysis of the demographic, clinical, and la-
boratory variables was performed using the R (http://
www.R-project.org) or Stata v14.0 (www.stata.com) soft-
ware. Normality of variables was assessed by a combin-
ation of skew/kurtosis metrics, visual inspection of the
histogram distribution and the Shapiro-Wilk normality
test. NLR/MLR did not meet normality criteria and was
therefore natural log (base e) transformed. Most other
variables were skewed so medians and interquartile
ranges are reported as opposed to means and standard
deviations. In our first set of analyses, we assessed which
demographic, treatment, and psychosocial variables were
associated with the concurrent natural log-transformed
NLR or MLR. For this analysis, we accounted for
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repeated observations on subjects using a linear mixed
effects model with a subject-specific random intercept.
Each potential predictor was included in the model sep-
arately in the univariable analysis. Further, a multivari-
able model including demographic factors, smoking
history and specific disease-modifying therapy (DMT)
use together was also fit to estimate the independent
association of each feature accounting for these covari-
ates. In addition to the analysis including all measure-
ments per subject, a separate univariate analysis
including only the most recent time point was per-
formed as well, and included as Additional file 1. In the
second set of analyses, we assessed whether NLR or
MLR was associated with clinical and radiologic
Table 1 Clinical and demographic characteristics, neuroimaging, and patient-reported outcomes
Variable Median (IQR) or N (%)
N 483
Age (years) 44.5 (36, 51.9)
Disease Duration (years) 8.8 (5.3, 16)
Neutrophil-lymphocyte ratio 2.1 (1.54, 2.9)
Monocyte-lymphocyte ratio 0.2 (0.15, 0.28)
Expanded Disability Status Scale 2 (1, 3)
Gender
• Female 347 (71.8%)
• Male 136 (28.2%)
Smoking Historya
• No 233 (54.2%)
• Yes 197 (45.8%)
Body mass index (BMI)a 26.2 (22.8, 31.1)
Multiple sclerosis disease category
• Clinically isolated syndrome 15 (3.1%)
• Relapsing-remitting 370 (76.6%)
• Secondary progressive 65 (13.5%)
• Primary progressive 33 (6.8%)
Disease modifying therapy
• Untreated 110 (22.8%)
• Interferon-β 216 (44.7%)
• Cyclophosphamide 14 (2.9%)
• Fingolimod 8 (1.7%)
• Glatiramer Acetate 51 (10.6%)
• Mycophenolate Mofetil 33 (6.8%)
• Natalizumab 37 (7.7%)
• Other 14 (2.9%)
Neuroimaging and patient-reported outcome measures Median (IQR); N
Brain parenchymal fraction 0.85 (0.81, 0.88); 334
Cerebral T2-hyperintense lesion volume (mL) 1.57 (1.27, 2.03); 334
Center for Epidemiological Studies Depression Scale 29 (24, 36); 479
Modified Fatigue Inventory Scale 29 (14, 41); 425
Modified Social Support Scale 85.4 (71.1, 98.4); 477
SF-36 Physical composite 46.6 (37.9, 54.3); 471
SF-36 Mental composite 50.9 (42.5, 56.4); 471
Legend: “Other” DMT includes combinations of or more of the following: methotrexate, azathioprine, pulsed glucocorticoids, anti-IL2 agents, rituximab,
natalizumab, interferons, glatiramer acetate, cyclophosphamide. Cyclophosphamide, methotrexate and mycophenolate mofetil were occasionally combined with
an interferon or glatiramer acetate; otherwise medications are listed as monotherapy. Median and interquartile ranges use data from patient’s most recent
available clinical visit. aSmoking history (N = 430), BMI (N = 402)
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measures of disease severity using a linear mixed effects
model with a subject specific random intercept. In this
model, the EDSS, BPF, cubic-transformed T2 lesion vol-
ume, and clinical disease category were the outcome
measures. We assessed the univariable association in-
cluding only NLR or MLR, and we also fit 2 different
multivariable models. Model 1 included demographic
and treatment predictors, whereas model 2 included
demographic, treatment and psychosocial predictors
to assess the independent contribution of NLR and
MLR on the outcomes. Lastly, we assessed whether
baseline NLR or MLR could predict subsequent (lon-
gitudinal) worsening of a patient’s MS-related disabil-
ity using EDSS as the outcome variable in a linear
mixed effects model with repeated measures. In this
model the predictor variables included time elapsed
(days) since baseline measurement, the natural
log-transformed MLR or NLR, and the interaction be-
tween the two maintained as continuous variables.
Results
Clinical, demographic, and self-reported outcomes
associated with the NLR and MLR
Univariable and multivariable associations between
demographic and psychosocial measures with NLR are pro-
vided in Table 2, and MLR in Table 3. In both univariable
and multivariable comparisons controlling for age, gender,
smoking history, and DMT, NLR was significantly higher
for subjects taking cyclophosphamide and fingolimod, and
significantly lower for subjects taking interferons and natali-
zumab. Increased NLR was also significantly associated
with higher depression (CES-D) scores, higher fatigue
scores (MFIS), and lower physical quality of life (SF-36),
but not social support as assessed by the MSSS, or BMI
(both p > 0.05). Uni- and multi-variable analyses with MLR
as the outcome showed similar significant associations with
the same DMTs as NLR except directionality reversal for
interferons; additionally, higher MLR significantly correlates
with older age, longer disease duration (univariable
Table 2 Clinical, demographic, and patient self-reported associations with the (natural log-transformed) Neutrophil-Lymphocyte
Ratio
Univariable Multivariable
β 95% CI p β 95% CI p
Age (yrs) 0.023 − 0.011, 0.056 0.188 0.021 − 0.010, 0.053 0.189
Disease Duration (yrs) 0.009 −0.023, 0.040 0.591 −0.013 − 0.048, 0.022 0.477
Gender
• Female – – – – – –
• Male −0.003 −0.083, 0.077 0.942 −0.012 −0.086, 0.062 0.750
Smoking History
• No – – – – – –
• Yes 0.001 −0.076, 0.078 0.979 0.018 − 0.054, 0.090 0.621
BMI −0.008 − 0.045, 0.029 0.666 0.002 −0.033, 0.037 0.910
DMT
• Untreated – – – – – –
• Interferon-β −0.166 − 0.236, − 0.096 < 0.001 − 0.163 −0.233, − 0.093 < 0.001
• Cyclophosphamide 0.268 0.147, 0.389 < 0.001 0.274 0.152, 0.395 < 0.001
• Fingolimod 1.044 0.767, 1.320 < 0.001 1.047 0.770, 1.323 < 0.001
• Glatiramer Acetate −0.082 −0.187, 0.024 0.131 −0.079 −0.185, 0.027 0.142
• Mycophenolate −0.072 −0.181, 0.037 0.197 −0.075 − 0.184, 0.035 0.181
• Natalizumab −0.529 −0.647, − 0.411 < 0.001 −0.526 − 0.644, − 0.408 < 0.001
• Other − 0.009 −0.141, 0.124 0.900 −0.012 − 0.144, 0.121 0.862
CES-D 0.034 0.008, 0.061 0.012 0.030 0.004, 0.055 0.022
MFIS 0.045 0.012, 0.078 0.008 0.035 0.004, 0.066 0.029
MSSS −0.019 −0.047, 0.010 0.203 −0.021 −0.048, 0.006 0.121
SF-36 Physical QOL −0.055 −0.086, − 0.024 < 0.001 −0.037 − 0.067, − 0.007 0.015
SF-36 Mental QOL − 0.024 −0.050, 0.003 0.086 −0.024 − 0.049, 0.002 0.066
Legend: CES-D Center for epidemiology scale for depression, MFIS Modified fatigue impact scale, MSSS Modified social support survey, QOL Quality of life, BMI
Body mass index, DMT Disease modifying therapy. Mixed linear regression models use data from all patient visits (repeated measures), with multivariable model
including the following covariates: age, gender, smoking history, and DMT use. Continuous predictor variables are Z-transformed such that one unit increase
represents one standard deviation change. Bolded values represent p < 0.05
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p < 0.01; multivariable p = 0.052) and male gender,
but not with any patient-reported outcome measures.
NLR/MLR are associated with MS-related disability and
neuroimaging outcomes
We then examined disease category (progressive vs. re-
lapsing), physical disability status (EDSS score), and neu-
roimaging outcome measures (BPF and T2LV) with
results summarized in Tables 4 and 5. In all models,
higher NLR and MLR were both robustly associated
with increased EDSS scores; effect sizes were slightly lar-
ger using MLR (β ~ 0.26) compared to NLR (β ~ 0.21).
Higher NLR and MLR both significantly discriminated
progressive from relapsing forms of MS in univariable
and basic multivariable analyses, although only NLR sig-
nificantly added to the complex multivariable analysis
Table 3 Clinical, demographic, and patient self-reported associations with the (natural log-transformed) Monocyte-lymphocyte Ratio
Univariable Multivariable
β 95% CI p β 95% CI p
Age (yrs) 0.051 0.019, 0.082 0.002 0.057 0.028, 0.086 < 0.001
Disease Duration (yrs) 0.043 0.013, 0.072 0.004 0.033 0.000, 0.065 0.049
Gender
• Female – – – – – –
• Male 0.163 0.090, 0.237 < 0.001 0.160 0.092, 0.229 < 0.001
Smoking History
• No – – – – – –
• Yes −0.002 −0.074, 0.070 0.958 0.003 −0.063, 0.069 0.937
BMI −0.031 −0.066, 0.003 0.074 −0.024 − 0.056, 0.007 0.132
DMT
• Untreated – – – – – –
• Interferon-β 0.068 0.004, 0.132 0.038 0.077 0.013, 0.140 0.018
• Cyclophosphamide 0.296 0.187, 0.406 < 0.001 0.310 0.201, 0.418 < 0.001
• Fingolimod 1.219 0.970, 1.469 < 0.001 1.207 0.959, 1.454 < 0.001
• Glatiramer Acetate −0.045 −0.142, 0.052 0.360 −0.047 −0.142, 0.049 0.339
• Mycophenolate 0.062 −0.037, 0.162 0.219 0.063 −0.035, 0.162 0.206
• Natalizumab −0.378 −0.486, − 0.270 < 0.001 −0.374 − 0.48, − 0.267 < 0.001
• Other 0.057 − 0.063, 0.178 0.350 0.048 −0.071, 0.168 0.426
CES-D 0.010 −0.015, 0.034 0.437 0.007 −0.016, 0.030 0.534
MFIS 0.008 −0.022, 0.038 0.604 0.005 −0.022, 0.033 0.704
MSSS 0.007 −0.019, 0.033 0.604 0.006 −0.018, 0.031 0.611
SF-36 Physical QOL −0.017 −0.045, 0.012 0.254 −0.011 − 0.038, 0.016 0.441
SF-36 Mental QOL −0.005 −0.030, 0.019 0.676 −0.005 − 0.027, 0.018 0.678
Legend: CES-D Center for epidemiology scale for depression, MFIS Modified fatigue impact scale, MSSS Modified social support survey, QOL Quality of life,
BMI Body mass index, DMT Disease modifying therapy. Mixed linear regression models use data from all patient visits (repeated measures), with multivariable
model including the following covariates: age, gender, smoking history, and DMT use. Continuous predictor variables are Z-transformed such that one unit
increase represents one standard deviation change. Bolded values represent p < 0.05
Table 4 Natural log-transformed neutrophil-lymphocyte ratio as a predictor of objective MS disease outcomes
Outcome Univariable Multivariable Model 1 Multivariable Model 2
β 95% CI p β 95% CI p β 95% CI p
EDSS 0.208 0.078, 0.338 0.002 0.238 0.106, 0.369 < 0.001 0.217 0.082, 0.351 0.002
RRMS v PMS 0.219 0.093, 0.344 0.001 0.599 0.350, 0.849 < 0.001 0.452 0.157, 0.747 0.003
BPF −0.001 −0.004, 0.002 0.610 −0.001 − 0.004, 0.001 0.243 − 0.002 −0.004, 0.001 0.156
T2LV −0.001 −0.032, 0.031 0.970 0.002 −0.031, 0.035 0.912 0.006 −0.029, 0.041 0.753
Legend: EDSS Expanded disability status scale, RRMS Relapsing-remitting multiple sclerosis, PMS Progressive multiple sclerosis, BPF Brain parenchymal fraction,
T2LV Cerebral T2-hyperintense lesion volume. All statistical models are linear mixed effects regressions. Multivariable model #1 includes the following covariates:
age, disease duration, gender, and specific DMT use. Model #2 includes the covariates: age, disease duration, gender, smoking history, specific DMT use, CES-D
score, MSSS score, SF-36 physical and mental composite scores
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(model 2) using age, disease duration, gender, smoking
history, DMT, depression, social support, and quality of
life measures as covariates (β = 0.45, p = 0.003). With
BPF as an outcome, higher MLR, but not NLR, was sig-
nificantly associated with greater whole brain atrophy in
all statistical models (p < 0.05). Lastly, neither NLR or
MLR were good correlates of T2 lesion volume, although
univariable comparison with MLR was borderline (p =
0.055). We did not include MFIS in the multivariable
model due to the decreased sample size (N = 424); when
we did include it, results (model #2) were similar. Given
the strong associations with DMT (Table 2), we also per-
formed sensitivity analyses using untreated patients only
(N = 146), and found 3–7 times increase in effect size for
associations with EDSS and disease category (relapsing
vs. progressive MS) in all linear models: see Additional
file 1 for full information.
NLR/MLR does not predict longitudinal worsening of
disability
Using only subjects with longitudinal data (N = 329,
1279 total observations), we tested whether baseline
(first measurement) NLR or MLR could predict subse-
quent worsening of EDSS using the interaction term:
(time elapsed)*(ln)M/NLR. This interaction was neither
significant in all subjects (NLR p = 0.15; MLR p = 0.22),
nor a subset of early relapsing patients (disease duration
< 5 years, N = 144, NLR p = 0.77; MLR p = 0.49), nor a
cohort of early relapsing untreated patients (N = 27, NLR
p = 0.08; MLR p = 0.64).
Discussion
The field of multiple sclerosis continues to lack a compre-
hensive serum biomarker for the diagnosis or monitoring
of disease activity. Here we present evidence that the com-
mon hematologic index ratios of neutrophil-to-lymphocyte
(NLR) and monocyte-to-lymphocyte (MLR) are both ro-
bustly associated with neurological disability scores in MS,
independent of all demographic and clinical variables. Add-
itionally, the MLR is associated with the MRI outcome of
whole brain atrophy (BPF), but not inflammatory burden of
T2-hyperintense cerebral lesions (T2LV). A higher NLR
(and MLR to a lesser extent) associate strongly with a diag-
nosis of progressive disease in MS. NLR, but not MLR, is
additionally associated with self-reported patient outcomes
including depression, fatigue, and quality of life, and
thus represents a psycho-neuro-immunological marker.
Strengths of this study include the large and
well-characterized sample of MS patients, including
self-reported psychological outcome measures, specific
DMT use, and quantified neuroimaging pathology. To-
gether this dataset allows robust statistical modeling and
higher confidence in the results; to our knowledge, this is
the largest report of NLR in multiple sclerosis, the first to
address confounding with DMT use, and include
characterization of neuroimaging findings; this is the first
reporting of the MLR in MS as well.
Our findings generally corroborate the limited prior
literature in this specific area, which consists of four
case-control, and one retrospective cohort study. All
case-control studies found significantly elevated NLR in
MS (or optic neuritis) compared to controls [13, 20, 22].
All groups found a mean NLR > 2.1 in MS compared to
healthy controls NLR < 2.1, however we urge caution be-
fore directly comparing trials since we found the CBC
analysis machine to be a significant source of variability
in our data and therefore excluded the use of the SYS-
MEX XE machine (results not shown). This methodo-
logical observation limits inter-study comparisons, and
carries implications for the role of NLR/MLR as poten-
tial biomarkers. Several of these prior studies also found
a higher NLR during flares compared to remission. We
did not attempt to replicate those results in our data due
to the uncertain timing of (likely) intravenous gluco-
corticoid administration during flares; this medication
would significantly elevate the NLR through demargina-
tion of neutrophils and we therefore excluded all CBC
measurements during flares.
Three studies have looked at the role of NLR as a cor-
relate of disability in MS; two of these demonstrated a
strong univariable [21] or multivariable [20] association,
discriminating EDSS scores of 5 and 3, respectively;
whereas one group found no significant value of NLR
to predict EDSS> 4 in a cross-sectional multivariable
Table 5 Natural log-transformed monocyte-lymphocyte ratio as a predictor of objective MS disease outcomes
Outcome Univariable Multivariable Model 1 Multivariable Model 2
β 95% CI p β 95% CI p β 95% CI p
EDSS 0.269 0.125, 0.413 < 0.001 0.256 0.108, 0.404 0.001 0.249 0.096, 0.401 0.001
RRMS v PMS 0.198 0.048, 0.347 0.010 0.407 0.158, 0.655 0.001 0.292 −0.062, 0.647 0.106
BPF −0.006 −0.010, − 0.003 < 0.001 −0.003 − 0.006, 0.000 0.043 − 0.003 −0.006, 0.000 0.040
T2LV 0.035 −0.001, 0.071 0.055 0.019 −0.019, 0.057 0.329 0.031 −0.009, 0.071 0.124
Legend: EDSS Expanded disability status scale, RRMS Relapsing-remitting multiple sclerosis, PMS Progressive multiple sclerosis, BPF Brain parenchymal fraction,
T2LV Cerebral T2-hyperintense lesion volume. All statistical models are linear mixed effects regressions. Multivariable model #1 includes the following covariates:
age, disease duration, gender, and specific DMT use. Model #2 includes the covariates: age, disease duration, gender, smoking history, specific DMT use, CES-D
score, MSSS score, SF-36 physical and mental composite scores
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model including age, gender, and disease duration [22];
this latter study also found no association with clinical
phenotype (relapsing vs progressive MS). Here, our results
support a strong association between higher NLR/MLR
and worse disability scores in robust multivariable models;
these measures are similarly able to significantly discrim-
inate progressive from relapsing patients. However, des-
pite robust correlations with disability and substantial
prior literature suggesting a role for the NLR in prognosti-
cation, a limited longitudinal analysis did not reveal a role
for NLR or MLR in predicting future disability worsening.
Our retrospective analysis was not properly designed to
answer this question however, so this data should be inter-
preted cautiously and further investigation is warranted.
The disease-modifying treatments used in the contempor-
ary treatment of MS are, by design, highly immunologically
active and clearly affect the NLR and MLR. Most DMTs ex-
cept glatiramer acetate have well-established (and possibly
nonlinear) effects on the numbers of circulating leukocytes;
most relevant here are fingolimod (lymphopenia/monocyto-
sis) [31], natalizumab (lymphocytosis) [32], cyclophospha-
mide (lymphopenia), and interferon-beta (lymphopenia/
neutropenia) [33], effects that are confirmed from our data
(Table 2). Overall these medications clearly limit the utility
of the NLR/MLR as cross-sectional bedside translational
markers- a challenge with any biomarker in MS. However,
these effects may be accounted for as covariates as we did
here; sensitivity analyses using only untreated patients typic-
ally made the associations between NLR/MLR and MS out-
comes such as EDSS even more robust (see Additional file
1). Ours is the only study in the literature to statistically ac-
count for the effects of DMT, and our results therefore sug-
gest a possible role in clinical translation, especially given the
low cost and widespread accessibility of this marker.
Lastly, Al-Hussain et al. [13] focused their paper on
the significant associations between NLR and psycho-
logical stress (p < 0.001). Whereas they did not find sig-
nificant associations with depression or anxiety, our
analysis demonstrated a small but highly significant as-
sociation between NLR and depression after controlling
for age, gender, smoking history and DMT, similar to re-
sults of a recent meta-analysis of NLR in mood disorders
[14]. We could not replicate prior findings of an associ-
ation between MLR and social support [34]. These psy-
choneuroimmunological associations should be further
explored as potential avenues of treatment that interact
with neuroinflammation.
More work is needed to better elucidate the mechanis-
tic immune feedback loops that presumably underlie the
origin of absolute myeloid and lymphocyte counts in the
circulating blood compartment; especially regarding the
(temporal) dynamics involved in relative rates of
leukocyte production, sequestration, egress, and survival
dynamics which are all integrated into these markers. In
a general sense, the numerator represents nonspecific
activation of the innate (myeloid) immune system, and
the denominator reflects suppression of more adaptive
processes. Higher circulating monocytes (MLR) were as-
sociated with greater whole brain atrophy and also with
male gender, the latter being a well-known risk for more
rapid disability accumulation [35]. The observation that
the NLR and MLR are significantly associated with
neuroinflammation-related disability, disease category,
and brain atrophy outcomes, also reflects current thinking
in the multiple sclerosis literature regarding a transition
from adaptive to (upregulated) innate immune processes
during the conversion phase from relapsing to progressive
clinical disease [36, 37]. This clinical transition is also
marked by a plateau effect of T2-hyperintense lesions
[38], a finding likely reflected in our data by the lack of as-
sociation between NLR/MLR and T2LV.
Multiple limitations exist in this study, perhaps most
importantly that our results are of an associative nature
only, and thus no conclusions should be drawn regarding
causality. Complex bidirectional relationships exist regard-
ing the connection between psychosocial (patient-reported)
factors, immune function, and disease outcomes; our study
only provides a limited insight into how these factors inter-
act. Additionally this study is limited by its retrospective na-
ture that is susceptible to selection and information biases;
these include unclear motivations for ordering CBCs
among untreated patients, or those on glatiramer acetate in
whom hematological monitoring is not required. Patients
in the untreated group may still be affected by prior drug
washout. Some of our cohort is missing neuroimaging out-
come data or patient-reported outcomes, which reduces
power in certain analyses and may bias results. Further, we
lack insight into subjects’ medical comorbidities or other
medication use which may affect the NLR/MLR. Lastly, the
CBC-d only provides a gross metric of immune function
and is limited in resolving lympocyte subsets such as Th1/
Th17 that are important in MS pathogenesis [39, 40].
Conclusions
As a readily available and widespread diagnostic and
monitoring tool, the NLR and MLR may represent trans-
lational metrics that can provide independent and com-
plementary cross-sectional information to a patient’s
inflammatory disease status in multiple sclerosis.
Additional file
Additional file 1: Tables S1-S4 Sensitivity analyses using cross-sectional
data only, using a single time point (subjects’ last clinic visit), and are
otherwise analogous to Tables 2, 3, 4 and 5 in the manuscript. Tables
S5. and S6. Sensitivity analyses using a subset of patients who were un-
treated (not on a disease-modifying therapy) at the time of their clinical
visit. (DOCX 53 kb)
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